Fulvic Acid Inhibits Aggregation and Promotes Disassembly of Tau Fibrils Associated with Alzheimer's Disease

被引:60
作者
Cornejo, Alberto [1 ]
Jimenez, Jose M. [1 ,2 ]
Caballero, Leonardo [3 ]
Melo, Francisco [3 ]
Maccioni, Ricardo B. [1 ,2 ]
机构
[1] Univ Chile, Int Ctr Biomed, Santiago, Chile
[2] Univ Chile, Lab Cellular & Mol Neurosci, Fac Sci, Santiago, Chile
[3] Univ Chile, Dept Phys, Santiago, Chile
关键词
Alzheimer's disease; atomic force microscopy; disassembly; fulvic acid; tau aggregation; SEED POLYPHENOLIC EXTRACT; NEUROFIBRILLARY TANGLES; TRANSGENIC MICE; MOUSE MODEL; IN-VITRO; TAUOPATHIES; MEMORY; BETA; PHENOTHIAZINES; DISORDERS;
D O I
10.3233/JAD-2011-110623
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Alzheimer's disease is a neurodegenerative disorder involving extracellular plaques (amyloid-beta) and intracellular tangles of tau protein. Recently, tangle formation has been identified as a major event involved in the neurodegenerative process, due to the conversion of either soluble peptides or oligomers into insoluble filaments. At present, the current therapeutic strategies are aimed at natural phytocomplexes and polyphenolics compounds able to either inhibit the formation of tau filaments or disaggregate them. However, only a few polyphenolic molecules have emerged to prevent tau aggregation, and natural drugs targeting tau have not been approved yet. Fulvic acid, a humic substance, has several nutraceutical properties with potential activity to protect cognitive impairment. In this work we provide evidence to show that the aggregation process of tau protein, forming paired helical filaments (PHFs) in vitro, is inhibited by fulvic acid affecting the length of fibrils and their morphology. In addition, we investigated whether fulvic acid is capable of disassembling preformed PHFs. We show that the fulvic acid is an active compound against preformed fibrils affecting the whole structure by diminishing length of PHFs and probably acting at the hydrophobic level, as we observed by atomic force techniques. Thus, fulvic acid is likely to provide new insights in the development of potential treatments for Alzheimer's disease using natural products.
引用
收藏
页码:143 / 153
页数:11
相关论文
共 35 条
  • [21] Leenheer J.A., 2007, ANN ENV SCI, V1, P57
  • [22] The molecular bases of Alzheimer's disease and other neurodegenerative disorders
    Maccioni, RB
    Muñoz, JP
    Barbeito, L
    [J]. ARCHIVES OF MEDICAL RESEARCH, 2001, 32 (05) : 367 - 381
  • [23] Reduction of soluble Aβ and Tau, but not soluble Aβ alone, ameliorates cognitive decline in transgenic mice with plaques and tangles
    Oddo, Salvatore
    Vasilevko, Vitaly
    Caccamo, Antonella
    Kitazawa, Masashi
    Cribbs, David H.
    LaFerla, Frank M.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (51) : 39413 - 39423
  • [24] Development of a grape seed polyphenolic extract with anti-oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathies
    Pasinetti, Giulio Maria
    Ksiezak-Reding, Hanna
    Santa-Maria, Ismael
    Wang, Jun
    Ho, Lap
    [J]. JOURNAL OF NEUROCHEMISTRY, 2010, 114 (06) : 1557 - 1568
  • [25] Cinnamon Extract Inhibits Tau Aggregation Associated with Alzheimer's Disease In Vitro
    Peterson, Dylan W.
    George, Roshni C.
    Scaramozzino, Francesca
    LaPointe, Nichole E.
    Anderson, Richard A.
    Graves, Donald J.
    Lew, John
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2009, 17 (03) : 585 - 597
  • [26] Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells
    Pickhardt, M
    Gazova, Z
    von Bergen, M
    Khlistunova, I
    Wang, YP
    Hascher, A
    Mandelkow, EM
    Biernat, J
    Mandelkow, E
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (05) : 3628 - 3635
  • [27] Inhibition of amyloid fibril formation by polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism
    Porat, Y
    Abramowitz, A
    Gazit, E
    [J]. CHEMICAL BIOLOGY & DRUG DESIGN, 2006, 67 (01) : 27 - 37
  • [28] 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
    Rinne, Juha O.
    Brooks, David J.
    Rossor, Martin N.
    Fox, Nick C.
    Bullock, Roger
    Klunk, William E.
    Mathis, Chester A.
    Blennow, Kaj
    Barakos, Jerome
    Okello, Aren A.
    de Llano, Sofia Rodriguez Martinez
    Liu, Enchi
    Koller, Martin
    Gregg, Keith M.
    Schenk, Dale
    Black, Ronald
    Grundman, Michael
    [J]. LANCET NEUROLOGY, 2010, 9 (04) : 363 - 372
  • [29] Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model
    Roberson, Erik D.
    Scearce-Levie, Kimberly
    Palop, Jorge J.
    Yan, Fengrong
    Cheng, Irene H.
    Wu, Tiffany
    Gerstein, Hilary
    Yu, Gui-Qiu
    Mucke, Lennart
    [J]. SCIENCE, 2007, 316 (5825) : 750 - 754
  • [30] Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins
    Taniguchi, S
    Suzuki, N
    Masuda, M
    Hisanaga, S
    Iwatsubo, T
    Goedert, M
    Hasegawa, M
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (09) : 7614 - 7623